share_log

Ardelyx | 10-Q: Quarterly report

Ardelyx | 10-Q: Quarterly report

Ardelyx | 10-Q:季度報表
美股SEC公告 ·  04:12

牛牛AI助理已提取核心訊息

Ardelyx, a biopharmaceutical company, has reported significant developments in its financial and business operations. The company has successfully managed its borrowing agreements, repaying a $25.0 million principal payment from a 2018 Loan and entering into a new loan agreement in 2022 with SLR Investment Corp. This new agreement provided Ardelyx with a $27.5 million Term A Loan, which was used to repay the 2018 Loan, and an additional $22.5 million Term B Loan funded in October 2023. Furthermore, Ardelyx has the option to draw an additional $50.0 million Term C Loan by March 15, 2024, and up to $50.0 million Term D Loan by December 31, 2026, subject to approval. The company has already drawn the Term C Loan to support the commercial launch of XPHOZAH and received the Term D Loan proceeds...Show More
Ardelyx, a biopharmaceutical company, has reported significant developments in its financial and business operations. The company has successfully managed its borrowing agreements, repaying a $25.0 million principal payment from a 2018 Loan and entering into a new loan agreement in 2022 with SLR Investment Corp. This new agreement provided Ardelyx with a $27.5 million Term A Loan, which was used to repay the 2018 Loan, and an additional $22.5 million Term B Loan funded in October 2023. Furthermore, Ardelyx has the option to draw an additional $50.0 million Term C Loan by March 15, 2024, and up to $50.0 million Term D Loan by December 31, 2026, subject to approval. The company has already drawn the Term C Loan to support the commercial launch of XPHOZAH and received the Term D Loan proceeds in October 2024. The maturity date for these loans has been extended to July 1, 2028. In terms of business development, Ardelyx has received U.S. FDA approval for XPHOZAH, a treatment for serum phosphorus reduction in adults with CKD on dialysis. This approval triggered a $1.5 million 2018 Exit Fee payment to lenders. The company has also achieved a Revenue Milestone, resulting in a $1.0 million 2022 Exit Fee payment. Ardelyx's future plans include the commercial launch of XPHOZAH and continued investment in the commercialization of IBSRELA and XPHOZAH, as well as manufacturing and development costs for tenapanor. The company has also entered into a Commercial Supply Agreement with Hovione for the manufacture of tenapanor API, with a term until December 31, 2030.
ardelyx,一家生物製藥公司,在其財務和業務運營方面取得了重大進展。該公司成功管理了借款協議,從2018年貸款中償還了2500萬美元的本金,並於2022年與slr investment corp簽訂了新的貸款協議。這份新協議爲ardelyx提供了2750萬美元的A期貸款,用於償還2018年的貸款,並於2023年10月獲得了另外2250萬美元的B期貸款。此外,ardelyx有權在2024年3月15日之前申請額外的5000萬美元的C期貸款,並在2026年12月31日之前申請最多5000萬美元的D期貸款,需經批准。該公司已經提取了C期貸款以支持XPHOZAH的商業推出,並於2024年10月收到了...展開全部
ardelyx,一家生物製藥公司,在其財務和業務運營方面取得了重大進展。該公司成功管理了借款協議,從2018年貸款中償還了2500萬美元的本金,並於2022年與slr investment corp簽訂了新的貸款協議。這份新協議爲ardelyx提供了2750萬美元的A期貸款,用於償還2018年的貸款,並於2023年10月獲得了另外2250萬美元的B期貸款。此外,ardelyx有權在2024年3月15日之前申請額外的5000萬美元的C期貸款,並在2026年12月31日之前申請最多5000萬美元的D期貸款,需經批准。該公司已經提取了C期貸款以支持XPHOZAH的商業推出,並於2024年10月收到了D期貸款的款項。這些貸款的到期日已延長至2028年7月1日。在業務發展方面,ardelyx已獲得美國FDA對XPHOZAH的批准,這是一種用於透析中患有CKD成人血清磷減少的治療藥物。此次批准觸發了對貸款人150萬美元2018年退出費的支付。該公司還實現了營業收入里程碑,導致對貸款人支付100萬美元的2022年退出費。ardelyx的未來計劃包括商業推出XPHOZAH,持續投資於IBSRELA和XPHOZAH的推廣以及對tenapanor的製造和發展成本。該公司還與Hovione簽訂了商業供應協議,用於生產tenapanor API,有效期直至2030年12月31日。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。